

NOVEL DRUG COMBINATIONS WITH BETI IN AN AR-INDEPENDENT MODEL OF PROSTATE CANCER

Markowski, Mark C M.D., Ph.D.¹; Hubbard, Gretchen Ph.D.²; Bieberich, Charles Ph.D.³; *De Marzo, Angelo M. M.D., Ph.^{1,2,4}*

Departments of Oncology¹, Pathology² and Urology⁴, Johns Hopkins University School of Medicine; Baltimore, MD

Department of Biological Sciences³, University of Maryland Baltimore County, Baltimore, MD

Background: The development of non-androgen receptor (AR) based therapies for metastatic castration resistant prostate cancer (mCRPC) is an unmet clinical need. Recently, chromatin modifying enzymes have emerged as important oncology drug targets and those targeting the so-called “reader” proteins that contain bromodomains (referred to as BET [bromodomain and Extra-Terminal proteins]) are particularly intriguing. Bromodomains are a conserved protein module that recognize and bind to acetylated lysines. Two main mechanisms have been put forth regarding how BET inhibitors (BETi) suppress tumor cells. First, these inhibitors can result in down regulation of MYC in cells that overexpress MYC, and second, they have been shown to inhibit activity of the androgen receptor. We have observed a growth inhibition effect of BETi in AR-negative models of prostate cancer including a novel murine model characterized by constitutive MYC expression.

Methods: We have established a new trigenic mouse model (referred to as BMPC) that features forced overexpression of MYC and deletion of Pten in the mouse prostate using the Hoxb13 transcriptional control elements. Upon developing invasive prostate cancer, this model losses expression of AR. We have generated two AR negative murine prostate cancer cell lines, BMPC-1 and BMPC-2, derived from metastatic deposits in these animals.

Results: We observed a significant effect of BETi on in vitro cell growth in both cell lines. Moreover, MYC expression, which is under the control of an exogenous promoter, was not reduced following BETi treatment. Similar growth suppressive effects were observed in human AR-negative prostate cancer cell lines. BETi in combination with both pan-PI3k and beta-specific PI3K inhibitors resulted in synergistic growth suppression in these models.

Conclusions: The finding of efficacy in an AR negative model of prostate cancer would suggest that AR negative prostate cancers (i.e. neuroendocrine, AR-negative adenocarcinoma) may derive clinical benefit from therapy. Also, suppression of growth in the BMPC cell lines appears independent of MYC inhibition. Thus, we obtained significant cell growth suppression without affect two of the main pathways assumed to mediate BETi effects. Furthermore, the use of novel drug partners with BETi, such as PI3K inhibitors, may improve the therapeutic index of BETi in the clinic.

COI: All authors report no conflict of interest

FUNDING: ASCO Young Investigator Award; DoD postdoctoral PCRP training award; Prostate Cancer Foundation Young Investigator Award